Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cel-Sci Corp
(NY:
CVM
)
1.125
-0.025 (-2.17%)
Streaming Delayed Price
Updated: 10:29 AM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cel-Sci Corp
< Previous
1
2
3
4
5
6
Next >
CVM Stock Earnings: CEL-SCI Misses EPS for Q3 2024
August 16, 2024
CVM stock results show that CEL-SCI missed analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
August 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering
August 02, 2024
Via
Investor Brand Network
Exposures
Product Safety
CEL-SCI Announces Closing of $10.8 Million Offering
July 29, 2024
From
CEL-SCI Corporation
Via
Business Wire
CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024
May 16, 2024
CEL-SCI just reported results for the second quarter of 2024.
Via
InvestorPlace
Why CEL-SCI Corporation (CVM) Shares Are Diving
February 09, 2024
CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares.
Via
Benzinga
CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023
December 27, 2023
CEL-SCI just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 26, 2024
Via
Benzinga
CEL-SCI Announces Pricing of $10.8 Million Offering
July 26, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
July 26, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Appoints Robert Watson as Chairperson of the Board
July 08, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
June 18, 2024
From
CEL-SCI Corporation
Via
Business Wire
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
June 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
May 16, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 09, 2024
Via
Benzinga
Why CEL-SCI (CVM) Shares Are Trading Higher
May 08, 2024
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy.
Via
Benzinga
Exposures
Product Safety
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
May 08, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 08, 2024
Via
Benzinga
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
April 23, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
March 19, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
March 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
February 15, 2024
From
CEL-SCI Corporation
Via
Business Wire
InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering
February 14, 2024
Via
Investor Brand Network
Exposures
Product Safety
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
February 13, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
February 09, 2024
Via
Benzinga
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
February 09, 2024
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
February 06, 2024
From
CEL-SCI Corporation
Via
Business Wire
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
January 31, 2024
From
CEL-SCI Corporation
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 28, 2023
Via
Benzinga
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
December 22, 2023
From
CEL-SCI Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.